This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract, valued at $476,414.19, is for the supply of Adenovirus Type 4 vaccine, a critical product that supports military immunization programs. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between Teva and the Department of Veterans Affairs (VA) National Acquisition Center, valued at $64,352,514.80, for the supply of glatiramer acetate injections for the treatment of multiple sclerosis. Teva also holds a separate $109,085,460 IDC with the VA for the supply of Albuterol HFA inhalers, and a $5,687,207.30 IDC with the DLA for Levalbuterol HCL Solution. These long-term, high-value contracts demonstrate Teva's critical role as a prime vendor of essential pharmaceutical products for various federal healthcare programs, including the VA, Department of Defense, Bureau of Prisons, and Indian Health Service. The contract does not have a set-aside designation, as Teva competes as a large business in unrestricted solicitations.
Generated 11/21/24, 9:19 AM